Larvol Delta - Evaluation-of-the-matrix-metalloproteinase-9-MMP9-inhibitor-Andecaliximab-as-an-Antiinvasive-therapeutic-in-Head-and-neck-squamous-cell-carcinoma

andecaliximab (GS-5745) - Gilead

http://www.ncbi.nlm.nih.gov/pubmed/35803110

Jul 9, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next